



## Sanofi Genzyme signs MOU with Tamil Nadu Dr. M.G.R. Medical University

~To support capacity building and upgrading diagnostic facilities to cater to the needs of patients with rare diseases and genetic disorders~

**Chennai, 01 March, 2018:** *Sanofi Genzyme*, the specialty care global business unit of Sanofi, and, *Tamil Nadu Dr. M.G.R. Medical University* (TNMGRMU) - India's second largest health sciences university, signed a **Memorandum of Understanding** (MOU) to support capacity building and upgrading diagnostic facilities - to cater to the needs of patients with rare diseases and genetic disorders.

The MOU was signed by N. Rajaram, Managing Director, Sanofi India; Dr. S. Geethalakshmi, Vice-Chancellor, TNMGRMU; and Dr. T. Balasubramanian, Registrar, TNMGRMU. According to the MOU, Sanofi Genzyme will support select students for a certified course in Cytogenetics (study of chromosomes and heredity). In addition, Sanofi Genzyme will also support Tamil Nadu Dr. M.G.R. Medical University in upgrading its diagnostic facilities to help detect abnormalities in a person's chromosomes.

**N. Rajaram, Managing Director, Sanofi India** said, *"We are glad to partner with Tamil Nadu Dr. M.G.R Medical University in their endeavor to build an ecosystem that can cater to the needs of patients with rare diseases and genetic disorders. The purpose of Academia-Industry collaborations like these is to take a step towards addressing one of the key aspects in building the ecosystem, i.e. capacity building. This association is an extension of Sanofi Genzyme's commitment towards working with the community of patients, physicians and researchers to enable effective diagnosis, focused education and access to treatment."*

Commenting on the partnership, **Dr. S Geethalakshmi, Vice-Chancellor, Tamil Nadu Dr. M.G.R. Medical University** said *"Our institute has always believed in offering holistic support which enhances medical research in the region and the country. Genetic study and analysis are the much-needed tools to help patients with rare or genetic disorders. To this end, Sanofi Genzyme is the perfect partner to help us improve the care that we can offer these patients."*

The Department of Medical Genetics at the Tamil Nadu Dr. MGR Medical University is engaged in pre-marital, pre-pregnancy, antenatal and postnatal counseling for patients from Tamil Nadu and the neighboring states. Unlike other institutes in the State, the Department of Medical

Genetics in the University is offering holistic support to the patients and families with genetic disorders. Genetic study and analysis are the much-needed tools to help patients suffering from rare or genetic disorders.

### **About TNMGRMU**

The Tamil Nadu Dr. M.G.R. Medical University is situated in Chennai (formerly Madras) in the State of Tamil Nadu, South India. This is the only Medical University in Tamil Nadu capable of granting affiliation to new institutions under Government or Self-financing in Medical, Dental, Indian Medicine/Homoeopathy & Allied Health Sciences (Pharmacy, Nursing, Physiotherapy, Occupational therapy etc.) and awarding degrees under a single umbrella to maintain uniform and high standards of education. Until 1988, all degrees of Health Sciences were awarded by the University of Madras.

### **About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Sanofi Genzyme, Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Pasteur, and Consumer Healthcare.

Sanofi Genzyme, the specialty care global business unit of Sanofi, is focused on rare diseases, multiple sclerosis, and immunology. It focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Sanofi Genzyme is recognized as one of the industry's most generous in-kind givers and 2018 marks the 20<sup>th</sup> year of Sanofi Genzyme's charitable access program in India. Through this program, known as INCAP (**IN**dia **C**haritable **A**ccess **P**rogram), Sanofi Genzyme is currently providing free Enzyme Replacement Therapy to patients with Lysosomal Storage Disorders (LSDs) in India.

### **Sanofi Forward-Looking Statements**

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

---

## **Contacts:**

### **Media Relations**

Aparna Thomas

Tel.: +91 22 2803 2169

[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)

Sohil Bahamania

Tel: +91 22 2803 2446

[sohil.bahamania@sanofi.com](mailto:sohil.bahamania@sanofi.com)